Opendata, web and dolomites

REUSABLE NGS LIBRARY

Reusable Back-up Library Construction and Storage Technology for Next Generation Sequencing (NGS) in Clinical Diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "REUSABLE NGS LIBRARY" data sheet

The following table provides information about the project.

Coordinator
Zip Prime Biyoteknoloji Limited Sirketi 

Organization address
address: Esk.Yol. Armada Is.M. Kat:12 Ofis No:1225Y2
city: Ankara
postcode: 6520
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Project website http://www.zipprime.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Zip Prime Biyoteknoloji Limited Sirketi TR (Ankara) coordinator 50˙000.00

Map

 Project objective

ZipPrime has recently developed a novel magnetic nanoparticle (MNP)-based Next Generation Sequencing (NGS) library construction technology which not only improves the NGS-based clinical diagnostic and high-throughput genomics workflow, but also has the novel and unique benefit of facilitating the construction of reusable backup NGS libraries without any additional workload via the MNPs, enabling subsequent sequencing of the same nucleic acid samples. Utilizing MNPs, this technology creates a reusable backup template of the prepared NGS diagnostic library which can be sequenced with NGS diagnostic panels whenever required, even after long-term storage. MNP-based reusable NGS products can be adapted to the workflows of all currently available NGS platforms and NGS diagnostic panels as a reusable backup solution with long term storage capabilities and/or a proof-reading solution to test the same sample again to prevent a false negative or false positive NGS diagnostic test results. After the recent FDA premarket approval for clinical diagnostic applications of NGS platforms, a new era for NGS has begun. However, despite these recent developments, NGS platforms are still using the same pre-sequencing sample preparation and library construction methods that were developed and optimized for scientific research. Unlike academic research applications, clinical applications of NGS require a reusable proof-reading solution with the capacity to store the constructed library for testing the same sample again. Although there are several alternative methods and products for the construction and enrichment of sequencing libraries for NGS systems, there is no current product in the NGS-based clinical diagnostic market that is validated for clinical applications and has the option of constructing reusable storage libraries. The proposed project aims to clinically validate the MNP-based reusable NGS product pipeline developed by ZipPrime for use in clinical NGS applications.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REUSABLE NGS LIBRARY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REUSABLE NGS LIBRARY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More